OBJECTIVES: Vascular endothelial growth factor (VEGF), a mediator of tumor-associated immunodeficiency, plays a key role in angiogenesis and is a prognostic factor in advanced ovarian cancer (AOC). Previously, we showed that low-dose interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) improved the tumor-associated immunodeficiency and decreased VEGF in patients with AOC. Here, we report long term follow-up of a group of patients with platinum-sensitive AOC who were treated with IL-2 and RA. METHODS: Sixty-five patients with AOC who had a clinical benefit from second line chemotherapy and elevated serum levels of VEGF were entered into the study from 04/98 to 04/05. Therapy consisted of low-dose subcutaneous IL-2 and oral RA, administered on intermittent schedules for up to 5 years. RESULTS: A statistically significant improvement in lymphocyte and NK counts and a decrease in VEGF levels were observed with respect to baseline values among the 65 evaluable patients. Five-year progression-free survival and overall survival rate were 29% and 38%, respectively. CONCLUSIONS: These data show that patients treated with low-dose IL-2 and RA have a statistically significant improvement in their lymphocyte and NK counts, a decrease in VEGF, and seem to have an improved clinical outcome. Copyright 2009 Elsevier Inc. All rights reserved.
OBJECTIVES:Vascular endothelial growth factor (VEGF), a mediator of tumor-associated immunodeficiency, plays a key role in angiogenesis and is a prognostic factor in advanced ovarian cancer (AOC). Previously, we showed that low-dose interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) improved the tumor-associated immunodeficiency and decreased VEGF in patients with AOC. Here, we report long term follow-up of a group of patients with platinum-sensitive AOC who were treated with IL-2 and RA. METHODS: Sixty-five patients with AOC who had a clinical benefit from second line chemotherapy and elevated serum levels of VEGF were entered into the study from 04/98 to 04/05. Therapy consisted of low-dose subcutaneous IL-2 and oral RA, administered on intermittent schedules for up to 5 years. RESULTS: A statistically significant improvement in lymphocyte and NK counts and a decrease in VEGF levels were observed with respect to baseline values among the 65 evaluable patients. Five-year progression-free survival and overall survival rate were 29% and 38%, respectively. CONCLUSIONS: These data show that patients treated with low-dose IL-2 and RA have a statistically significant improvement in their lymphocyte and NK counts, a decrease in VEGF, and seem to have an improved clinical outcome. Copyright 2009 Elsevier Inc. All rights reserved.
Authors: Justin M Drerup; Yang Liu; Alvaro S Padron; Kruthi Murthy; Vincent Hurez; Bin Zhang; Tyler J Curiel Journal: Curr Treat Options Oncol Date: 2015-01
Authors: Eric Tran; Julie S Nielsen; Darin A Wick; Alvin V Ng; Lisa D S Johnson; Nancy J Nesslinger; Elissa McMurtrie; John R Webb; Brad H Nelson Journal: PLoS One Date: 2010-12-22 Impact factor: 3.240
Authors: Locke D Uppendahl; Carly M Dahl; Jeffrey S Miller; Martin Felices; Melissa A Geller Journal: Front Immunol Date: 2018-01-05 Impact factor: 7.561
Authors: Sarah Nersesian; Haley Glazebrook; Jay Toulany; Stephanie R Grantham; Jeanette E Boudreau Journal: Front Immunol Date: 2019-08-09 Impact factor: 7.561